Pathology of mammary glands in women with reproductive disorders and chronic endometritis

• Main Authors: I. N. Danusevich, L. F. Sholokhov, K. V. Sukhinina, E. B. Druzhinina, A. A. Semendyaev
• Format: Article
• Language: Russian
• Published: Scientific Сentre for Family Health and Human Reproduction Problems 2018-05-01
• Series: Acta Biomedica Scientifica
• Subjects: chronic endometritis; reproductive disorders; mammary glands; hormones
• Online Access: https://www.actabiomedica.ru/jour/article/view/578

Background. The last decades are devoted to the search for various factors leading to the development of benign breast diseases, which are the risk of breast cancer. In gynecological diseases, the frequency of benign processes in the mammary glands increases to 76-97.8 %. Aims: this research is devoted to the study of the prevalence and structure of breast pathology in women with chronic endometritis and reproductive disorders. Materials and methods. The study included patients with reproductive disorders: 50 patients with histological verification of the diagnosis of chronic endometritis and 50 patients without chronic endometritis. Hormonal examination was carried out using radioimmunoassay and immunoenzymatic methods. Methods of mathematical statistics implemented Statistica 6.1 (USA) were used parametric criteria: Student's t-test and Fisher's F-criterion, the nature of the distribution was estimated using the methods of Kolmogorov - Smirnov with a significance level smaller and equal to 5 % (p < 0.05). To confirm the fact that the observed differences between the products of A x D and B x C are not random, we used the х2 criterion. Results and conclusions. In women with chronic endometritis, the pathology of the mammary glands is characterized by the presence of ectasia of the ducts of the mammary gland; clinically, it is manifested by lactorrhea. Benign dysplasia of mammary glands is accompanied by the presence of hyperestrogenia, hypoprogesteronemia, which is typical for ovarian dysfunction. It is possible to use a pathogenetically reasonable combination correction: anti-inflammatory therapy and the use of gestagens in women with reproductive disorders and chronic endometritis.